-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 29, 2024

Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

Author(s)Kirollos S. Hanna, PharmD, BCPS, BCOP, Hope Rugo, MD, Joyce O’Shaughnessy, MD

Dr. Rugo details her management strategy in regards to GI toxicities.

Episodes in this series

EP. 1 Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP. 1 Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP. 2 Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP. 2 Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP. 3 Outcomes from NATALEE and MonarchE

EP. 3 Outcomes from NATALEE and MonarchE

EP. 4 Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

EP. 4 Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

A panel of 4 experts on breast cancer

EP. 5 Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

A panel of 4 experts on breast cancer

EP. 6 Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

A panel of 4 experts on breast cancer

EP. 7 Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

A panel of 4 experts on breast cancer

EP. 8 Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

A panel of 4 experts on breast cancer

EP. 9 Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

A panel of 4 experts on breast cancer

EP. 10 How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

A panel of 4 experts on breast cancer

EP. 11 Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

A panel of 4 experts on breast cancer

EP. 12 Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

A panel of 4 experts on breast cancer

EP. 13 ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Video content above is prompted by the following question(s):

What specific strategies do you use for mitigating gastrointestinal toxicities associated with abemaciclib in the adjuvant setting?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Stamp that says "FDA Approved" in blue ink. | Image Credit: Surendra - stock.adobe.com

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

ByElla Hohmann, MS

June 25th 2026

Health care professional holding up blocks with the text saying "FDA Approval". | Image Credit: wladimir1804-stock.adobe.com.jpeg

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance

ByElla Hohmann, MS

June 24th 2026

Principal investigator Sara A. Hurvitz, MD, said results with the gedatolisib combinations show they could be the new standard of care in HR+/HER2- advanced breast cancer. | Image: Fred Hutch

In VIKTORIA-1, Gedatolisib Combos Cut Risk of Progression by Half vs Alpelisib in PIK3CA-Mutant Advanced Breast Cancer

June 19th 2026

Iain MacPherson, MD, PhD, FRCP, professor of breast oncology at the University of Glasgow, discusses results from the OPTIMA trial. | Image: BreastCancer.org

OPTIMA: Prosigna Test Finds Which Patients With Breast Cancer Can Skip Chemotherapy

ByElla Hohmann, MS

June 19th 2026

Coral Omene, MD, PhD | Image Credit: Rutgers Cancer Institute

Access and Disparity Questions Around Rilvegostomig+T-DXd: Coral Omene, MD, PhD

ByElla Hohmann, MS,Coral Omene, MD, PhD

June 15th 2026

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis

More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor

EHA Data for Epcoritamab Show Durable Responses in Older, Chemotherapy-Ineligible Patients With DLBCL